Posts By: pharmanewsdaily

KIK-AS clinical trial : Angelman syndrome drug candidate GTX-102 to be evaluated by GeneTx Biotherapeutics

GeneTx Biotherapeutics is set to start the KIK-AS clinical trial for evaluating GTX-102 for the treatment of Angelman syndrome (AS), a rare, neurogenetic disorder resulting from the loss-of-function of the maternally inherited allele of the UBE3A gene. In this connection, the biotech startup has secured institutional review board (IRB) approval from Rush University Medical Center […]

Epizyme gets FDA priority review for TAZVERIK in follicular lymphoma

Epizyme has been granted priority review by the US Food and Drug Administration (FDA) for the use of TAZVERIK (tazemetostat) in relapsed or refractory follicular lymphoma (FL). As per the new drug application (NDA) that has been accepted by the FDA, the Massachusetts-based biopharma company is seeking the accelerated approval of the methyltransferase inhibitor for […]

ALX Oncology raises $105m to advance clinical development of ALX148

ALX Oncology, a clinical-stage immuno-oncology company based in California, has raised $105 million in a Series C equity financing round led by Vivo Capital. The US biotech company is focused on developing therapies to block the CD47 checkpoint mechanism. ALX Oncology will use the Series C proceeds to help expand the clinical development of its […]

ALX Oncology raises $105m to advance clinical development of ALX148

ALX Oncology, a clinical-stage immuno-oncology company based in California, has raised $105 million in a Series C equity financing round led by Vivo Capital. The US biotech company is focused on developing therapies to block the CD47 checkpoint mechanism. ALX Oncology will use the Series C proceeds to help expand the clinical development of its […]

ImmunogenX enrolls patients for Solutions for Celiac trial of Latiglutenase

ImmunogenX, a subsidiary of Immunogenics, has started enrollment of patients for a phase 2b clinical trial to evaluate Latiglutenase (IMGX003), its lead candidate for the treatment of celiac disease. The mid-stage clinical trial, called Solutions for Celiac trial (NCT04243551) is funded by the US’ National Institutes of Health’s (NIH) National Institute of Allergy and Infectious […]

Pinpoint Therapeutics secures funds for developing autophagy inhibitors for cancer

Pinpoint Therapeutics, a US biopharma company focused on developing autophagy inhibitors for cancer treatment, has secured $1 million in debt financing led by California-based venture capital firm Kairos Ventures. The preclinical stage company was founded in 2018 through PCI Ventures, a division of the Penn Center for Innovation (PCI) at the University of Pennsylvania. It […]

Antios Therapeutics begins phase 1 trial for ATI-2173, a chronic hepatitis B candidate

US biopharma company Antios Therapeutics has initiated its first-in-human phase 1 clinical trial for ATI-2173, a liver-targeted, orally-administered, small molecule against hepatitis B. The phase 1a study is a randomized, double-blind, placebo-controlled single-ascending dose (SAD) study that will feature healthy volunteers to assess the safety, tolerability and pharmacokinetic profile of the compound. The SAD trial […]

Australian clinical diagnostics company SpeeDx raises $15m in Series B round

SpeeDx, an Australian clinical diagnostics company, to support improved patient outcomes, has secured $15 million in a Series B funding round from US-based investor Northpond Ventures. The company has developed a molecular diagnostics test portfolio, mainly for infectious diseases, that offers identification and also therapeutic guidance capabilities. Michael P. Rubin – Founder and CEO of […]

PCI acquires Canadian pharma packaging company Bellwyck Pharma Services

PCI Pharma Services, a pharma supply chain solutions provider, has acquired Canada-based pharma packaging company Bellwyck Pharma Services for an undisclosed price. Bellwyck Pharma Services has been serving the clinical trial and commercial drug markets with primary and secondary packaging and labeling for 25 years. Its acquisition will give four GMP-compliant facilities for PCI Pharma […]

Catalent Pharma Solutions acquires cell and gene therapy CDMO MaSTherCell

Drug manufacturer Catalent Pharma Solutions has wrapped up its previously announced $315 million acquisition of MaSTherCell Global, a technology-focused cell and gene therapy contract development and manufacturing organization (cell and gene therapy CDMO). The acquisition, which was announced earlier this month, is said to position Catalent as a major technology, development, and manufacturing partner for […]

Scroll To Top